PolyPid Ltd. (PYPD)
$6.31
+0.10 (+1.61%)
Rating:
Recommendation:
-
| Symbol | PYPD |
|---|---|
| Price | $6.31 |
| Beta | 0.896 |
| Volume Avg. | 0.02M |
| Market Cap | 123.368M |
| Shares () | - |
| 52 Week Range | 3.92-9.64 |
| 1y Target Est | - |
| DCF Unlevered | PYPD DCF -> | |
|---|---|---|
| DCF Levered | PYPD LDCF -> | |
| ROE | -107.05% | Strong Sell |
| ROA | -128.29% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 23.01% | Neutral |
| P/E | - | |
| P/B | 4.14 | Strong Buy |
Latest PYPD news
About
Download (Excel)PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.